Clinical trials: Cancer Progression
High Grade Glioma, Glioblastoma
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.
- Trial name
- NCT05565118
- Testing
- Standard Surgical Treatment, Intraoperative Electrocorticography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Neoplasm, Breast, Congenital, Familial and Genetic Disorders
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
The study is a nationwide, multicenter single-arm phase 2 study. The current phase 2 study investigates the efficacy of the combination of fulvestrant and alpelisib directly after progression on fulvestrant (either in first or…
- Trial name
- SEQUEL-Breast (NCT05392608)
- Testing
- Alpelisib 150 MG Oral Tablet [Piqray], Fulvestrant
- Where
- 25 sites in Netherlands
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Borstkanker Onderzoek Groep
Breast Cancer
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line…
- Trial name
- NCT00929240
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 63 sites in Brazil, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00538291
- Testing
- cetuximab, capecitabine, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Amyloidosis, Hereditary
Prospective Evaluation of NfL as a Biomarker in ATTRv
ATTR amyloidosis is a rare and progressively disabling disease caused by the deposition of misfolded TTR protein in multiple tissues including the nerves, heart, and gastrointestinal tract.
- Trial name
- NfLInATTRv (NCT05879874)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Crohn's Disease
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
The purpose of this study for children with a new diagnosis of Crohn's disease is to identify biomarkers found in the blood or stool to help predict which children are at risk of developing complications.
- Trial name
- RS (NCT00790543)
- Where
- 28 sites in United States, Canada
- Volunteers
- 1,813 people
- Sponsor
- Emory University
HIV Infection and Chronic Alanine Aminotransferase Elevation
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection.
- Trial name
- NCT01208376
- Testing
- Fibroscan
- Where
- Switzerland
- Volunteers
- 195 people
- Sponsor
- Helen Kovari-Kramer
Metastatic Colorectal Cancer
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
Colorectal cancer is the 2nd leading cause of cancer death in France. Its incidence is nearly 45,000 new cases per year in 2017, with an estimated 5-year survival of 63% in 2015.
- Trial name
- NCT05299840
- Testing
- Oncogramme results available, Oncogramme results unavailable
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Oncomedics
Biomarkers, Cognitive Assessment
Neuropsychological Indicators of SCD Progression
Some patients with subjective cognitive decline (SCD) progress to neurocognitive disorders (NCD), whereas others remain stable; however, the neuropsychological determinants of this progression have not been identified.
- Conditions
- Biomarkers, Cognitive Assessment, Cognitive Decline, Neurocognitive Disorders
- Trial name
- SCD-CI (NCT04880252)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatitis C
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
The investigators will conduct a randomized controlled clinical trial study in an urban emergency department in Baltimore to determine the impact of an educational app which is based on Leventhal's Common-Sense Model of Illness…
- Trial name
- NCT04162938
- Testing
- Patient-Centered Electronic App
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- Johns Hopkins University
Gastric Cancer
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Trial name
- NCT01216644
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 716 people
- Sponsor
- Krankenhaus Nordwest
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Anesthesia, Surgical Procedure, Operative
The Bern Perioperative Biobank
The goal of the research is to define clinically relevant molecular markers for increased risk of peri-/ postoperative organo-dysfunctions, inflammation, adverse events and disease progression.
- Trial name
- BPBB (NCT04767685)
- Where
- Switzerland
- Volunteers
- 547 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cancer Progression
Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
This study examines the role of this simple technique on postoperative metastasis and long term survival.
- Trial name
- NCT02319863
- Testing
- hepatectomy (conventional method), hepatectomy (rapid ligating)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Huazhong University of Science and Technology
Multiple Myeloma
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.
- Trial name
- NCT06209606
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
ARDS, ARDS Disease Progression
Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding
COVID-19 resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the respiratory sequelae after an acute distress respiratory syndrome (ADRS).
- Trial name
- TENACITY (NCT06083363)
- Where
- 3 sites in Spain
- Volunteers
- 246 people
- Sponsor
- Institut de Recerca Biomèdica de Lleida
Multiple Sclerosis
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
The relative effectiveness of current treatments and their different mechanisms of action yield to consider more and more that the multiple sclerosis (MS) therapeutic approach must use multiple molecules, both combined and…
- Trial name
- MITOX-REBIF (NCT02937285)
- Testing
- Interferon beta 1a, Mitoxantrone
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Glaucoma
Macular Damage in Early Glaucoma and Progression
Glaucoma is the leading cause of irreversible blindness worldwide. This study aims to test a new method that may allow earlier diagnosis of glaucoma and better ways to monitor if it is getting worse.
- Trial name
- NCT02547740
- Where
- United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Columbia University
Dental Caries
Resin Infiltration to Arrest Early Tooth Decay
The purpose of this study is to determine whether lesion infiltration is an effective management strategy to arrest early tooth decay.
- Trial name
- NCT01584024
- Testing
- Resin infiltration
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with…
- Conditions
- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
- Trial name
- NCT06577376
- Testing
- DP303c, Simmitinib tablets, Irinotecan liposomes
- Volunteers
- 252 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.